Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 97 Neoplasms 28 Carcinoma, Non-Small-Cell Lung 27 Neoplasm Metastasis 23 Urinary Bladder Neoplasms 17 Colorectal Neoplasms 17 Sarcoma 15 Lung Neoplasms 14 Biliary Tract Neoplasms 13 Ovarian Neoplasms 12 Lymphoma, Large B-Cell, Diffuse 12 Breast Neoplasms 12 Lymphoma 10 Cholangiocarcinoma 10 Recurrence 9 Hodgkin Disease 8 Carcinoma, Transitional Cell 8 Adenocarcinoma 8 Lymphoma, Non-Hodgkin 7 Triple Negative Breast Neoplasms 6 Non-Muscle Invasive Bladder Neoplasms 6 Lymphoma, Follicular 6 Stomach Neoplasms 5 Small Cell Lung Carcinoma 5 Rectal Neoplasms 5 Gastrointestinal Neoplasms 5 Colonic Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 4 Multiple Myeloma 4 Lymphoma, T-Cell, Peripheral 4

Interventions

pembrolizumab 2 Paclitaxel 2 Carboplatin 2 poly(I).poly(c12,U) 1 liposomal doxorubicin 1 Lenalidomide 1 Interferon alpha-2 1 Gemcitabine 1 Cisplatin 1 Bevacizumab 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Ovarian Cancer Recurrent × Gemcitabine × Clear all

NCT06843447 2026-05-26

MK-5909-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡